Literature DB >> 12359770

Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo.

Manali S Bendre1, Dana Gaddy-Kurten, Thetsu Mon-Foote, Nisreen S Akel, Robert A Skinner, Richard W Nicholas, Larry J Suva.   

Abstract

Metastasis is the process by which tumor cells spread from their site of origin to distant sites after gaining access to the circulatory system. An understanding of the factors contributing to the metastatic potential of breast cancer cells to bone will enhance the prospect of developing new therapies that impede metastasis. In this study, we have used an in vivo selection scheme involving left cardiac ventricle injection into nude mice to identify a highly metastatic human breast cancer cell line (MDA-MET) from a less metastatic (MDA-231) parental cell line. In this model, tumor-bearing mice exhibit features similar to those associated with human metastatic bone disease such as osteolytic bone destruction. After inoculation, MDA-MET cells form devastating lesions within 4 weeks, whereas the parental cells do not, even after 10 weeks. In vitro, the MDA-MET cells have a similar growth rate to the parental MDA-231 cells yet demonstrate distinct adhesive and invasive phenotypes. MDA-MET cells show increased early adhesion to type IV collagen and are significantly more invasive through Matrigel than MDA-231 cells. Analysis of the gene expression profile in the metastatic MDA-MET versus poorly metastatic MDA-231 cells identified relatively few genes whose expression was altered >2-fold. Of particular interest was the lack of parathyroid hormone-related protein (PTHrP) mRNA expression, which was supported at the protein level by immunoradiometric assay. These data support the idea that PTHrP is not predictive of the metastasis of human breast cancer to bone. Another important difference between the two cell lines was the elevated expression by MDA-MET cells of the cytokine IL-8. Reverse transcriptase-PCR and ELISA confirmed the increased expression of IL-8 in MDA-MET cells. In addition, IL-8 mRNA expression is also elevated in a variety of human cancer cell lines with different metastatic potential in vivo. These experiments suggest that the elevated expression of IL-8 (and not PTHrP) by MDA-MET cells is a phenotypic change that may be related to their enhanced ability to metastasize to the skeleton.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359770

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  66 in total

1.  Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.

Authors:  Ruth Schwaninger; Cyrill A Rentsch; Antoinette Wetterwald; Geertje van der Horst; Rutger L van Bezooijen; Gabri van der Pluijm; Clemens W G M Löwik; Karin Ackermann; Walter Pyerin; Freddie C Hamdy; George N Thalmann; Marco G Cecchini
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

2.  Alterations in Cx43 and OB-cadherin affect breast cancer cell metastatic potential.

Authors:  Zhongyong Li; Zhiyi Zhou; Henry J Donahue
Journal:  Clin Exp Metastasis       Date:  2008-01-10       Impact factor: 5.150

Review 3.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

4.  Ex-vivo analysis of the bone microenvironment in bone metastatic breast cancer.

Authors:  Karen M Bussard; Andrea M Mastro
Journal:  J Mammary Gland Biol Neoplasia       Date:  2009-12-02       Impact factor: 2.673

5.  Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.

Authors:  Ahmed Boucharaba; Claire-Marie Serre; Sandra Grès; Jean Sébastien Saulnier-Blache; Jean-Claude Bordet; Julien Guglielmi; Philippe Clézardin; Olivier Peyruchaud
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 6.  Hallmarks of Bone Metastasis.

Authors:  Rachelle W Johnson; Larry J Suva
Journal:  Calcif Tissue Int       Date:  2017-11-14       Impact factor: 4.333

7.  A role for leukemia inhibitory factor in melanoma-induced bone metastasis.

Authors:  Shigeaki Maruta; Soichi Takiguchi; Miho Ueyama; Yasufumi Kataoka; Yoshinao Oda; Masazumi Tsuneyoshi; Haruo Iguchi
Journal:  Clin Exp Metastasis       Date:  2008-10-25       Impact factor: 5.150

8.  Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.

Authors:  Anurag Purushothaman; Ligong Chen; Yang Yang; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2008-09-23       Impact factor: 5.157

9.  Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity.

Authors:  Linda Hughes; Catherine Malone; Saranya Chumsri; Angelika M Burger; Susan McDonnell
Journal:  Clin Exp Metastasis       Date:  2008-04-02       Impact factor: 5.150

10.  Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.

Authors:  Lauren K Dunn; Khalid S Mohammad; Pierrick G J Fournier; C Ryan McKenna; Holly W Davis; Maria Niewolna; Xiang Hong Peng; John M Chirgwin; Theresa A Guise
Journal:  PLoS One       Date:  2009-09-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.